1029 related articles for article (PubMed ID: 24710123)
1. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of
Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
[TBL] [Abstract][Full Text] [Related]
3. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
4. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
5. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
8. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
12. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
Onal C; Guler OC; Reyhan M; Yapar AF
Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
[TBL] [Abstract][Full Text] [Related]
14. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
15. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.
Oh D; Ahn YC; Park HC; Lim DH; Noh JM; Cho WK; Pyo H
Oncotarget; 2017 May; 8(22):35700-35706. PubMed ID: 28415687
[TBL] [Abstract][Full Text] [Related]
18. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.
Abd El-Hafez YG; Moustafa HM; Khalil HF; Liao CT; Yen TC
Oral Oncol; 2013 Mar; 49(3):261-8. PubMed ID: 23036774
[TBL] [Abstract][Full Text] [Related]
19. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
Guler OC; Torun N; Yildirim BA; Onal C
Br J Radiol; 2018 Apr; 91(1084):20170552. PubMed ID: 29293366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
